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AbstrACt
Introduction A potential link exists between prostate 
cancer (PCa) disease and treatment and increased 
inflammatory levels from gut dysbiosis. This study aims 
to examine if exercise favourably alters gut microbiota 
in men receiving androgen deprivation therapy (ADT) 
for PCa. Specifically, this study will explore whether: (1) 
exercise improves the composition of gut microbiota and 
increases the abundance of bacteria associated with 
health promotion and (2) whether gut health correlates 
with favourable inflammatory status, bowel function, 
continence and nausea among patients participating in the 
exercise intervention.
Methods and analysis A single-blinded, two-armed, 
randomised controlled trial will explore the influence of 
a 3-month exercise programme (3 days/week) for men 
with high-risk localised PCa receiving ADT. Sixty patients 
will be randomly assigned to either exercise intervention 
or usual care. The primary endpoint (gut health and 
function assessed via feacal samples) and secondary 
endpoints (self-reported quality of life via standardised 
questionnaires, blood biomarkers, body composition 
and physical fitness) will be measured at baseline and 
following the intervention. A variety of statistical methods 
will be used to understand the covariance between 
microbial diversity and metabolomics profile across time 
and intervention. An intention-to-treat approach will 
be utilised for the analyses with multiple imputations 
followed by a secondary sensitivity analysis to ensure data 
robustness using a complete cases approach.
Ethics and dissemination Ethics approval was obtained 
from the Human Research Ethics Committee of Edith 
Cowan University (ID: 19827 NEWTON). Findings will be 
reported in peer-reviewed publications and scientific 
conferences in addition to working with national support 
groups to translate findings for the broader community. If 
exercise is shown to result in favourable changes in gut 
microbial diversity, composition and metabolic profile, 
and reduce gastrointestinal complications in PCa patients 
receiving ADT, this study will form the basis of a future 
phase III trial.
trial registration number ANZCTR12618000280202.
IntroduCtIon
Gut microbiota play a fundamental role in 
protection from pathogens, in the induction 
and function of the immune system and in 
the promotion of digestion and absorption 
of dietary nutrients for energy production.1 2 
Indeed, perturbations of the composition and 
function of gut microbiota can cause gastroin-
testinal (GI) complications, and contribute to 
the pathogenesis of metabolism and disease 
processes such as inflammation, infection 
and tumours.3–6 
Androgen deprivation therapy (ADT) is 
extensively used as a neoadjuvant, adjuvant 
and/or standalone treatment for men with 
prostate cancer (PCa);6 however, survivors 
are burdened with persistent adverse effects 
of ADT including GI complications.7–11 
strengths and limitations of this study
 ► This trial comprises a comprehensive analysis of 
gut microbiome in individuals with prostate cancer, 
addressing a significant and increasingly emergent 
issue in this area.
 ► A two-armed, randomised controlled trial design to 
examine proof of concept and provide effect sizes 
to design subsequent appropriately powered trials.
 ► Lack of follow-up past 13 weeks prohibits any as-
sessment of sustainability of effects.
 ► The inclusion criteria prevent generalisability to the 
other types of cancer.
 ► Diet and physical activity (outside of the interven-
tion) will not be tracked and are limitations of the 
current design.
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Despite a paucity of research into the mechanisms asso-
ciated with GI diseases in PCa survivors, it is hypothesised 
that a dysbiotic composition of the gut microbiome may 
mediate negative outcomes of GI complications associ-
ated with PCa.12–15 Indeed, results from murine models 
demonstrate that castration and antiandrogens can affect 
the composition of gut microbiota.16 17 The complex, 
dynamic interaction between sex hormones and gut 
microbiome is still poorly understood.18 Nevertheless, 
Markle et al19 demonstrated that elevated levels of testos-
terone in female mice results in favourable changes in 
microbiota, metabolomics and inflammation, lending 
potential support for the role of ADT in adverse changes 
to gut microbiota.19 20 To address gut dysbiosis, especially 
for those with cancer, recent interventions have focused 
on the use of probiotics or prebiotics to alleviate symp-
toms,2 indicating that the manipulation of gut micro-
biota could be a viable therapeutic strategy for men with 
PCa.21 22
Perhaps unsurprisingly, emerging evidence indicates 
that exercise may exert a positive effect on gut microbial 
composition.2 23 In non-cancer cohorts, a link between 
exercise and gut microbial diversity, composition and 
beneficial metabolite production has been illustrated.24 25 
Of note, the ratio of Firmicutes to Bacteroidetes phyla is 
of particular importance, with obese individuals having a 
higher Firmicutes to Bacteroidetes ratio which is indicative 
of poorer gut health.26 27 Importantly, it has been consis-
tently demonstrated that men on ADT experience consid-
erable unfavourable shifts in body composition, indicated 
by a significant loss of lean body mass coupled with an 
increase in fat mass.28–30 Consequently, men on ADT may 
be at a heightened risk for this altered ratio of Firmic-
utes to Bacteroidetes. The shift in relative abundances of 
these phyla is suggested to result in an increased ability to 
harvest energy from food and promote low-grade inflam-
mation.31 Whereas, a microbiota in homeostasis and the 
presence of Lactobacillus and Bifidobacterium can exert 
anti-inflammatory effects at local and systemic levels, indi-
cating a potential link between the gut microbiota health 
and inflammatory status.32
Metabolites are molecules that have critical roles in 
cellular metabolism, energy production and storage, 
apoptosis and signal transduction, and are affected by 
diet, exercise and gut microbiota among others. Indeed, 
the metabolomic profile has been suggested to be indic-
ative of disease state in cancer and identified as a poten-
tial biomarker of the development and progression of 
PCa.33 Consequently, an exploration of the relationships 
between changes in gut microbiota composition, metab-
olomic profile, inflammatory status and bowel function 
could have important clinical implications through 
enhancing positive exercise-induced effects on these 
outcomes through the manipulation of the composition 
of gut microbiota. Although the potential for exercise 
to modulate gut microbiota is promising, a paucity of 
research in the area exists, particularly in individuals at 
risk for gut dysbiosis. As such, no prior investigation has 
been conducted to determine whether gut microbiota 
composition is influenced by exercise in PCa survivors.34
The aim of this exploratory study is to determine the 
effect of exercise medicine on gut microbiota and its 
metabolome in men receiving ADT for PCa. Specifically, 
we will explore whether: (1) exercise improves compo-
sition of the gut microbiota and increases abundance 
of health-promoting bacterial species, thereby driving 
an advantageous faecal metabolomic profile and (2) 
improved gut health correlates with favourable inflam-
matory status, bowel function, continence, nausea and 
appetite among patients participating in the exercise inter-
vention. It is hypothesised that the exercise programme 
will result in favourable changes in the composition of 
gut microbiota, and that these changes will be correlated 
with improvements in inflammatory status, bowel func-
tion and other GI issues. This study will serve to provide a 
better understanding of whether the gut microbiota and 
its metabolites can be modulated by exercise as a poten-
tial therapeutic target that can be offered for PCa patients 
on ADT.
MEthods
study design
This is a single-blinded (investigators blinded to group 
allocation), randomised controlled trial, designed to 
measure the impact of a supervised exercise medicine 
intervention on gut microbiota and its metabolome of PCa 
patients receiving ADT. An ‘exercise’ group will receive 
a 12-week supervised exercise programme comprising 
aerobic and resistance exercise undertaken three times 
per week. A ‘usual care’ group will continue to receive 
usual medical care during the trial. The usual care group 
will be offered an exercise programme following their 
control period to minimise study contamination and to 
reduce patient withdrawal and loss to follow-up.
Participants
Sixty men (n=60) with high-risk localised PCa, defined 
by the National Comprehensive Cancer Network as 
T3a disease, Gleason ≥8 or prostate- specific antigen 
(PSA) ≥20,35 who are currently on ADT (and expected 
to remain on ADT for the next 3 months) are eligible to 
enrol in this study and will be randomised to exercise or 
usual care. ADT can be achieved with either luteinising 
hormone-releasing hormone (LHRH) agonists or LHRH 
antagonists, or a combination of the two. It is also accept-
able for patients to receive no >4 weeks of antiandrogen 
at the initiation of their ADT to prevent flare from testos-
terone surge. Patients must be on continuous ADT during 
the study period.
Participants will be excluded if they have any nodal, 
visceral or bone metastases (N1 or M1 disease); are being 
treated for other cancers; previously received or currently 
receiving chemotherapy; currently receiving radiation 
therapy or any non-approved experimental therapies; 
and/or previously had any prior GI surgery. Patients will 
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also be excluded if they have taken antibiotics, prebi-
otics, probiotics, nutritional or ergogenic compliments 
or supplements within 3 months prior to study enrol-
ment; have recently had a prostatectomy, orchiectomy or 
received radiation therapy within 12 months prior to 
study enrolment; have any physical, mental or other 
contraindications to exercise; and/or cannot (or have 
difficulty) understanding English. Participants will be 
excluded if they currently engage in regular, structured 
physical activity (aerobic or resistance training for two 
or more times per week in the previous 3 months). All 
participants must receive medical clearance from their 
managing physician to be eligible to enrol. Additionally, 
all participants will be asked to provide informed consent 
prior to the start of any study activities.
recruitment
Men with localised or locally advanced PCa, who are 
currently receiving ADT, will be recruited by invitation of 
their attending specialist (ie, urologist or radiation oncol-
ogist), who will provide clinically eligible patients with a 
study information sheet and referral to the study coor-
dinator. If patients are interested in participation, and 
their eligibility is confirmed, they will receive an informed 
consent document to read and sign in the presence of 
a study investigator and/or clinical research coordinator 
prior to completing baseline measures and randomis-
ation. Figure 1 outlines the process of referrals, recruit-
ment and enrolment in the trial.
randomisation
PCa patients will be randomly allocated in a ratio of 
1:1 to two study arms: exercise or usual care, stratified 
by age (≤60 and  >60 years), time on ADT (≤6 and >6 
months) and prior prostatectomy or radiation therapy 
(Yes and No) for approximate balance between groups in 
order to mitigate confounding factors pertaining to vari-
ations due to ageing (ie, differences in physical function, 
sarcopenia, osteopenia and osteoporosis) and to account 
for variations in treatment. All patients will be required to 
be on ADT prior to, and during the study, as per standard 
of care for this patient population. A research officer with 
no patient contact will be responsible for the randomisa-
tion of patients into groups using a computer-generated 
random assignment programme. Study investigators and 
the exercise physiologists conducting testing procedures 
will be blinded to group allocation. Only exercise phys-
iologists who are not part of the research team will be 
permitted to deliver the exercise intervention to partic-
ipants in order to maintain integrity of the blinding 
process.
Measurements
Table 1 outlines the primary and secondary endpoints 
that will be undertaken at baseline (week 0) and postin-
tervention (week 13). All procedures and assessment 
tools have proven validity and reliability and are used 
widely throughout clinical research.
Primary endpoint
Gut health and dysbiosis
Gut health will be assessed through the provision of 
a 24-hour collection of stool sample(s), subsequently 
examined and analysed for microbial composition (using 
bacterial DNA), bacterial metabolites and for faecal calpro-
tectin. Briefly, participants will be provided with a 24-hour 
collection kit for collection of all bowel movements within 
that time. The kit includes a high-performance cooler bag 
(Techni Ice), two gel ice packs (Techni Ice), collection 
bags, Bristol stool chart to classify stool and instructions. 
The cooler bag has been tested in our laboratory to main-
tain temperature at 4°C for 24–36 hours, and 4°C has been 
shown to not significantly alter faecal microbiota diversity 
or composition.36 In addition, we have also showed that 
there is no significant difference in faecal short-chain fatty 
acid (SCFA) levels between cool temperature storage and 
Figure 1 Consolidated Standards of Reporting Trials 
diagram.
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immediate freezing of the stool sample at −20°C (data not 
shown). Samples will be returned to the laboratory within 
12–24 hours following collection and stored at −80°C in 
a biomedical freezer (Forma 88700 ULT; Thermo Fisher 
Scientific, Waltham, Massachusetts , USA) until they are 
homogenised (combined if >1 sample over the 24 hours) 
and partitioned into aliquots for analysis.
To extract microbial DNA, samples will be lysed using 
both mechanical and enzymatic breakdown of the 
bacterial cell membranes and the DNA extracted using 
the QIAamp PowerFecal DNA kit (Qiagen; Hilden, 
Germany). Microbiome signatures will be generated using 
the Illumina MiSeq platform using barcoded primer, V4 
(515–806). Quality control samples are included in the 
analysis from sample collection to sequence analysis and 
all samples will be individually screened for PCR effi-
ciency prior to building sequence libraries. For building 
the sequence libraries, a PCR-free ligation protocol 
will be deployed with sample barcodes that are never 
reused in our laboratory. Samples will be sequenced to 
a depth of minimum 30 000 reads, which is sufficient to 
identify microbes to a genus/species level. Quantitative 
polymerase chain reaction (qPCR) will be used to verify 
shifts observed in the sequence data and will therefore be 
determined postanalysis of the 16S rRNA gene data. This 
will provide a detailed picture of longitudinal changes in 
gut microbial community structure with treatment and 
following exercise.
Sequence read quality will be initially assessed with 
quality control software (FASTQC, https://www. bioinfor-
matics. babraham. ac. uk/ projects/ fastqc/) before demul-
tiplexing and preprocessing by Shi737 and/or GHAPv2. 
Clutadapt will be used for removal of all non-biological 
sequences.38 DADA2 is then used for quality filtering, 
error correction, Amplicon Sequence Variance (ASV) 
picking.39 A trained naïve Bayes classifier then assigns 
ASVs to genus/species against a curated database of 
microbial reference sequences such as the RDP40 or 
SILVA.
The faecal metabolome contains over 6000 known 
endogenous and exogenous metabolites, comprised of 
many classes, each with unique chemical properties; thus, 
no single analytical platform can be used to measure the 
entire metabolome in a single assay. Untargeted metabo-
lite profiles (>2000 metabolite features) will be measured 
in faecal samples using high-throughput mass-spec-
trometry technologies consisting of two complementary 
analytical platforms in six modes of operation: gas chroma-
tography high resolution mass spectrometry (GC-HRMS) 
with electronc impact (EI) and chemical ionization (CI) 
modes; and liquid chromatography high resolution mass 
spectrometry (LC-HRMS) (reverse phase and hydro-
philic interaction (HILIC) chromatography with both 
positive and negative ionisation modes). Resulting data 
will provide a comprehensive systems overview of metab-
olome disruption of the gut microbiota due to PCa and 
ADT, as well as alterations resulting from the exercise 
intervention. All analyses will be performed at the Centre 
for Integrative Metabolomics & Computational Biology 
(CiMCB; Edith Cowan University, Perth, Australia). Addi-
tional targeted analysis methods will be used for accurate 
quantification of SCFAs; formate, acetate, propionate, 
butyrate, isobutyrate, valerate and isovalerate metabolites. 
Faecal calprotectin will also be measured as a biomarker 
of inflammation to monitor gut inflammation.41
secondary endpoints
Dietary behaviour
Habitual dietary intake will be assessed using the Dietary 
Questionnaire for Epidemiological Studies (DQES V.2.0; 
Cancer Council of Victoria, Melbourne, Australia) which 
is a modified food frequency questionnaire relevant to 
cancer populations. A research assistant will supervise 
the completion of the DQES and use food models and 
charts, metric cups and spoons to increase accuracy. All 
participants will be instructed to maintain their habitual 
dietary patterns throughout the study. DQES data will be 
collated and batch analysed at the conclusion of the study 
by the Nutritional Assessment Office (Cancer Council 
of Victoria). Dietary analysis will include food item 
frequency and a comprehensive nutrient intake analysis.
Biomarkers
Fasted blood samples will be collected and analysed 
commercially by an accredited National Association of 
Testing Authorities laboratory (Australian Clinical Labs, 
Perth, Australia) for glucose, high-sensitivity C-reactive 
protein, tumour necrosis factor-alpha, IL-6, cholesterol 
(total, high-density lipoprotein, low-density lipoprotein), 
testosterone and PSA. Additional serum (serum separator 
tube (SST), 8 mL) and plasma (EDTA, 9 mL) samples will 
be collected at baseline and postintervention visits by a 
certified phlebotomist, and will be processed and stored in 
Table 1 Schedule of assessments at baseline and 
postintervention
Measures Baseline Postintervention
Medical history x
Gut health (24-hour stool sample) x x
Dietary behaviour (DQES) x x
Blood biomarkers x x
Cancer-specific quality of life
  EORTC-QLQ-C30 x x
  EORTC-PR-25 x x
Body composition (DXA) x x
Muscle strength (1RM) x x
Aerobic fitness (400 m) x x
Physical function tests x x
DQES, Dietary Questionnaire for Epidemiological Studies; EORTC-
QLQ-C30, European Organisation for Research and Treatment 
of Cancer Quality of Life Questionnaire Core 30; EORTC-PR-25; 
EORTC-Prostate Cancer Module 25; 1RM, one-repetition 
maximum. 
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a −80°C biomedical freezer (Forma 88700 ULT; Thermo 
Fisher Scientific) for subsequent metabolomics analysis 
at the CiMCB. For participants that provide consent, the 
samples will be stored for a duration of 5 years. We will 
be pursuing other research studies in advanced cancer 
patients, and this deidentified blood sample data may be 
of use to gain further insights and comparisons. For partic-
ipants who do not provide consent for future storage (but 
do provide consent for this study), we will destroy any left-
over samples following the analysis required for this study 
(within 6 months from time of patient enrolment).
Clinical data
PCa participant medical history, including PCa diagnosis 
(ie, Gleason score, stage of cancer, months since diag-
nosis, treatment history and time on ADT), comorbidities 
(ie, hypertension, osteoarthritis and others), concomitant 
medications (ie, opioids, beta-blockers, antihypertensives, 
blood cholesterol and others) and other diagnosed chronic 
diseases (ie, osteoporosis, diabetes, cardiovascular disease 
and others) will be sourced from patient medical records. 
Further, information pertaining to any related history of 
bowel symptoms,42 GI symptoms43 and other bowel-related 
conditions (Bristol Stool Chart)44 will also be obtained.
Quality of life, bowel function, continence, nausea and appetite
Cancer-specific quality of life indices will be measured using 
the European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30,45 assessing 
five functional scales (physical, role, emotional, cognitive 
and social functioning), three symptom scales (fatigue, pain, 
nausea and vomiting), a global health scale and six single 
items (dyspnea, insomnia, appetite loss, constipation, diar-
rhoea and financial difficulty). PCa-specific quality of life 
indices will be measured using the EORTC-Prostate Cancer 
Module 25,46 assessing urinary symptoms, bowel symptoms, 
treatment-related symptoms and sexual functioning.
Anthropometric and body composition measures
Stature will be recorded to the ~1 cm using a wall-mounted 
stadiometer (Model 222, Seca, Hamburg, Germany), with 
body mass recorded to the ~0.1 kg using an electronic scale 
(AE Adams CPW Plus-200, Adam Equipment, Connecticut, 
USA). Whole body fat percentage, fat mass and lean mass 
will be measured using Dual-energy X-ray Absorptiometry 
(DXA; Horizon A, Hologic, Marlborough, Massachusetts, 
USA), with whole-body and appendicular segmentations 
generated in accordance with Hart and colleagues.47
Physical fitness
A battery of standard tests will be used to assess physical 
fitness, including (1) muscle strength, using one-repetition 
maximum (1RM) tests for chest press, seated row and leg 
press exercises; (2) aerobic fitness, using the 400 m walk test 
and (3) physical function, using the timed up and go, 6 m 
walk test (normal, fast and backward) and repeated chair 
rise.48 49
Exercise programme
Patients assigned to the exercise arm will attend three clin-
ic-based supervised exercise sessions each week for 12 weeks 
consisting of moderate-to-high intensity resistance and 
aerobic exercise (interval and continuous). Each session will 
take ~60 min, including warm-up and cool-down, and will 
be supervised by accredited exercise physiologists (Exercise 
and Sports Science Australia). The exercise programme is 
designed to provide optimal stimulus to the cardiorespira-
tory and neuromuscular systems while maximising safety, 
compliance and retention, thus will be tailored, progres-
sive, periodised and autoregulated in collaboration with the 
patient (ie, adjusted based on the patient’s presentation at 
each session).
Resistance exercise will be prescribed using repeti-
tion maximums (RM), where patients will be required to 
perform 6–8 different resistance exercises using major 
muscle groups, at 6–12 RM (the maximal weight that can 
be lifted 6–12 times each set, equivalent to ~60%–85% of 
1RM) for 3–4 sets per exercise to achieve moderate-to-
high intensity and volume. Aerobic exercise will include 
20–30 min of moderate-to-vigorous intensity activity 
(equating to ~60%–85% of estimated maximum heart rate; 
or a rating of perceived exertion [RPE] between 6 and 8 
using the BORG 10 point scale50) involving a variety of 
modes including walking, jogging, cycling or rowing, using 
treadmills and/or stationary ergometers. Aerobic inten-
sity will be monitored using heart rate monitors (Polar 
M400, H10 Sensor, Polar Electro, NSW, Australia) and 
an RPE chart for assessment. Patients will also be encour-
aged to perform additional aerobic exercise (such as brisk 
walking), outside of their supervised exercise clinic visits, 
progressing towards accruing a volume of activity consistent 
with national guidelines for health (ie, 150 min of physical 
activity, or a further ~60–90 min self-managed). Participants 
will be provided log books to detail aerobic activity, which 
will be reviewed in the clinic each week. Flexibility exercises 
for all joints considered important for function and for all 
muscles engaged during the session will be provided during 
the cool-down phase of each exercise session.
statistical analysis
These sample sizes (n=30 per group, totalling n=60) have 
been chosen to determine a moderate standardised effect 
(d=0.8) for the primary and most secondary outcome 
measures (alpha=0.05).
A variety of statistical methods will be used to understand 
the covariance between microbial diversity and metab-
olomics profile across time and intervention, including 
using classical parametric and non-parametric univariate 
statistical methods (eg, repeated measure analysis of vari-
ance [ANOVA]), as well as multivariate projection models 
(such as principal components analyses and partial least 
squares discriminant analyses). The purpose of this initial 
stage of data analysis will be to uncover latent correlated 
biochemical structure in the data, mapping metabolite 
concentrations to metabolic pathways and ultimately to 
determine candidate metabolic signatures associated with 
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dysregulation of the gut microbiome. The resulting metab-
olite signatures will be integrated with quantified SCFA 
measurements to contextualise the results. The metab-
olomic and metagenomic data will be integrated using 
latent structure projection techniques including OnPLS,51 
Multiblock Component Analysis52 and Regularised Gener-
alised Canonical Correlation Analysis,53 which extracts a 
minimal number of globally predictive orthogonal latent 
components that exhibit maximal covariance and correla-
tion between data blocks. This will allow us to perform 
metabolite functional mapping, which will allow us to start 
unpacking the biochemical mechanism of microbiome/
exercise interaction.
Statistical analyses will also include descriptive character-
istics, t-tests, effect size and two-way (group x time) repeated 
measures ANOVA (or analysis of covariance, adjusted for 
baseline values, time on ADT and medication change). For 
categorical variables, Pearson chi-square will be used. Data 
will be examined using an intention-to-treat approach with 
multiple imputations followed by a secondary sensitivity 
analysis to ensure data robustness using a complete cases 
approach. Data will be completely deidentified, and subse-
quently coded in order to note which group/intervention a 
patient received; without any ability to identify the patient in 
any way. Any identifiable documents will be destroyed. The 
deidentified information will be kept electronically only, in 
a password locked folder, on a password locked computer, 
accessible only by the team investigators. All statistical tech-
niques employed in this study will be implemented using 
open source software (R or Python), which will be made 
publicly available at the time of dissemination.
Adverse events
Individuals will be monitored for any adverse events during 
exercise testing and training and will be documented 
accordingly. The study team has extensive experience in 
delivering exercise specifically tailored to individuals with 
PCa in a safe and efficacious manner. The risks of adverse 
events are low in this study and a data monitoring/safety 
committee has not been appointed.
Patient and public involvement
The Exercise Medicine Research Institute (EMRI) has 
consumer representatives (cancer patients, survivors 
and their family members) who volunteer their time to 
provide input into research directions and study designs. 
Furthermore, the study clinicians (CIT, RC) consult within 
the major public and private hospitals in Perth, Western 
Australia, each with high PCa caseloads, thus have used 
patient priorities, patient experience and patient pref-
erences to help inform the development of the research 
questions and outcome measures, while aiding the study 
protocol to engage participants in a respectful, ethical and 
impactful way.
Ethics and dissemination
Any amendments to the protocol will be submitted to and 
reviewed the HREC and trial registration will be updated 
accordingly. If exercise is proven to result in favourable 
changes in gut microbial diversity, composition and meta-
bolic profile, and reduce GI complications (inflamma-
tion, constipation, diarrhoea and nausea) in PCa patients 
receiving ADT, this study will form the basis of a future 
phase III trial. These outcomes will provide further vali-
dation of exercise medicine in this population and add 
to efforts aimed at changing clinical practice. To reach a 
maximum number of clinicians, practitioners, patients 
and scientists, the results of this study will be published 
in international, high-impact peer-reviewed clinical and 
academic journals. In addition, outcomes will be dissemi-
nated through national and international clinical, medical 
or academic conferences and oncology clinic and patient 
meetings. Finally, EMRI and the broader study team work 
closely with the Prostate Cancer Foundation of Australia 
(PCFA), their support groups and states offices. PCFA will 
assist in the translation and dissemination of the research 
findings to community members, and cancer support 
groups, while study participants will receive their individual 
results in addition to overall study findings.
dIsCussIon
PCa patients are burdened with persistent adverse effects 
of treatment, including GI complications.7–11 It has 
been hypothesised that the hormonal consequences of 
ADT may have an adverse effect on the composition of 
gut microbiota.20 Perturbations of the composition and 
function of gut microbiota can cause GI complications 
and contribute to the development and pathogenesis 
of metabolism and disease processes such as inflamma-
tion, infections and disease progression.14 Additionally, 
the metabolomic profile of PCa patients could be an 
important biomarker for disease state and progression.33 
Consequently, an examination of therapeutic strategies 
to induce clinically meaningful improvements in the 
gut microbiome, metabolomic profile and inflammatory 
status is warranted.
Preliminary evidence indicates that exercise, indepen-
dent of diet, may result in favourable changes in gut micro-
bial diversity and composition, which has the potential to 
improve overall metabolic and health profile.54 While this 
research is promising, much of this area is in its infancy, 
with a substantial lack of evidence in a cancer context. 
Given the paucity of data, coupled with the potential nega-
tive health effects of gut dysbiosis in PCa, there is a clear 
need to directly evaluate the relationship between exer-
cise and gut microbiota in this patient population. The 
protocol outlined in this paper will evaluate the effects of 
exercise on changes in the composition and diversity of 
gut microbiota and if these changes are correlated with 
favourable inflammatory status, bowel function, conti-
nence, nausea and appetite among patients participating 
in the exercise intervention.
Excess adiposity is associated with a heightened inflam-
matory state and gut dysbiosis.55 Exercise has been previ-
ously demonstrated to successfully attenuate and/or 
 o
n
 20 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024872 on 14 April 2019. Downloaded from 
7Newton RU, et al. BMJ Open 2019;9:e024872. doi:10.1136/bmjopen-2018-024872
Open access
reverse the accumulation of fat mass experienced by PCa 
patients undergoing ADT.48 49 56 Consequently, it is biolog-
ically plausible that improvements in lean body mass 
and overall body composition may mediate favourable 
changes in the composition of gut microbiota, inflamma-
tory status and metabolomic profile. Moreover, gut dysbi-
osis has been associated with frailty in older adults.57–60 
Though a causal relationship cannot be determined, 
improvements in muscle strength and physical function 
from exercise may contribute to improvements in the 
composition of gut microbiota in this population. Conse-
quently, analysis of body composition and physical fitness 
will provide valuable information on any factors that may 
mediate changes in gut microbiome from exercise.60
LIMItAtIons
Despite the novel study design, several limitations should 
be acknowledged. Though a dietary intervention and/or 
more rigorous tracking throughout the study would be 
interesting, limitations in funding, resources and feasi-
bility make it difficult to do this in the current study. An 
interesting aspect would be to examine the differential 
efficacy in androgen blockade, sex hormone conver-
sion in the patient and subsequent exercise intervention 
effects. However, this is not possible in the current study 
and thus a limitation of the investigation is the ability to 
link androgen kinetics directly to the primary outcomes. 
Additionally, although this study will be one of the first to 
examine changes in gut microbiota with exercise in men 
with ADT, the lack of follow-up precludes an analysis of 
the sustainability of outcomes.
ConCLusIons
If demonstrated that this exercise intervention results 
in clinically meaningful improvements in gut health, 
the outcomes of this trial will provide innovative, new 
evidence that can inform the design of future phase III 
clinical trials to further elucidate the effects of exercise 
on gut health in patients with PCa. Further, any correla-
tions between changes in the composition and diversity 
of gut microbiota and inflammatory status, and GI issues, 
may inform design of future research studies that further 
explore these relationships.
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